← Back
The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday. Gilead reported fourth-quarter revenue of $7.6 billion, up 6% year over year
+6.1% closed: 2024-11-10
Gilead Sciences’ stock price surge reflects a growing investor confidence in the company’s ability to deliver sustainable growth. The company’s strategic focus on therapeutic areas beyond its core offerings positions Gilead for continued success
Stock Swings
Price Drops
No drop incidentsPrice Hikes
+11.54% closed: 2025-02-15+6.1% closed: 2024-11-10
Gilead Sciences’ stock price surge reflects a growing investor confidence in the company’s ability to deliver sustainable growth. The company’s strategic focus on therapeutic areas beyond its core offerings positions Gilead for continued success